Unione Europea - italiano - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - immunosoppressori - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. il trattamento di grave, attiva e progressiva artrite reumatoide negli adulti non precedentemente trattati con metotressato. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita riduce il tasso di progressione del danno articolare misurato da x-ray e migliora la funzione fisica, quando somministrato in combinazione con metotressato. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita può essere somministrato come monoterapia in caso di intolleranza al metotressato o quando il trattamento continuato con metotressato è inappropriato (per l'efficacia in monoterapia vedere la sezione 5. adalimumab non è stato studiato in pazienti di età inferiore a 2 anni. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita riduce il tasso di progressione del danno articolare periferico come misurato da raggi x in pazienti con poliarticolare simmetrica sottotipi della malattia (vedere la sezione 5. 1) e migliora la funzione fisica. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 e 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - adalimumabum - soluzione iniettabile in penna preriempita - adalimumabum 40 mg, histidinum, histidini hydrochloridum monohydricum, dinatrii edetas corresp. natrium 5 µg, saccharum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - rheumatoide arthritis, polyartikuläre juvenile arthritis, psoriasis-arthritis, ankylosierende spondylitis, morbus crohn bei erwachsenen, kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, uveitis - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - adalimumabum - soluzione iniettabile in siringa preriempita - adalimumabum 40 mg, histidinum, histidini hydrochloridum monohydricum, dinatrii edetas corresp. natrium 5 µg, saccharum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - rheumatoide arthritis, polyartikuläre juvenile arthritis, psoriasis-arthritis, ankylosierende spondylitis, morbus crohn bei erwachsenen, kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, uveitis - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - adalimumabum - soluzione iniettabile - adalimumabum 40 mg, histidinum, histidini hydrochloridum monohydricum, dinatrii edetas corresp. natrium 5 µg, saccharum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad suspensionem pro 0.8 ml. - polyartikuläre juvenile arthritis, morbus crohn bei kindern und jugendlichen - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - adalimumabum - soluzione iniettabile in penna preriempita - adalimumabum 40 mg, saccharum, polysorbatum 80, acidum aceticum glaciale, natrii hydroxidum corresp. natrium max. 0.26 mg, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - l'artrite reumatoide, polyartikuläre l'artrite idiopatica giovanile, artrite psoriasica, spondilite anchilosante (spondilite anchilosante), la malattia di crohn negli adulti, la colite ulcerosa, psoriasi nell'adulto - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - adalimumabum - solution injectable en seringue préremplie avec protège-aiguille - adalimumabum 40 mg, acidum aceticum, natrii acetas trihydricus corresp. natrium 0.07 mg, glycinum, polysorbatum 80, aqua ad iniectabile ad solutionem pro 0.4 ml. - polyarthrite rhumatoïde, arthrite juvénile idiopathique polyarticulaire, arthrite psoriasique, spondylarthrite ankylosante, maladie de crohn chez l'adulte, colite ulcéreuse, psoriasis chez l'adulte, l'adolescent et l'enfant, hidradénite suppurée, uvéite - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - adalimumabum - soluzione per iniezione in pre-riempita penna - adalimumabum 40 mg, acidum aceticum, natrii acetas trihydricus corresp. natrium 0.07 mg, glycinum, polysorbatum 80, aqua ad iniectabile ad solutionem pro 0.4 ml. - polyarthrite rhumatoïde, arthrite juvénile idiopathique polyarticulaire, arthrite psoriasique, spondylarthrite ankylosante, maladie de crohn chez l'adulte, colite ulcéreuse, psoriasis chez l'adulte, l'adolescent et l'enfant, hidradénite suppurée, uvéite - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - adalimumabum - solution injectable en seringue préremplie avec protège-aiguille - adalimumabum 80 mg, acidum aceticum, natrii acetas trihydricus corresp. natrium 0.14 mg, glycinum, polysorbatum 80, aqua ad iniectabile ad solutionem pro 0.8 ml. - polyarthrite rhumatoïde, arthrite juvénile idiopathique polyarticulaire, arthrite psoriasique, spondylarthrite ankylosante, maladie de crohn chez l'adulte, colite ulcéreuse, psoriasis chez l'adulte, l'adolescent et l'enfant, hidradénite suppurée, uvéite - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - adalimumabum - soluzione per iniezione in pre-riempita penna - adalimumabum 80 mg, acidum aceticum, natrii acetas trihydricus corresp. natrium 0.14 mg, glycinum, polysorbatum 80, aqua ad iniectabile ad solutionem pro 0.8 ml. - polyarthrite rhumatoïde, arthrite juvénile idiopathique polyarticulaire, arthrite psoriasique, spondylarthrite ankylosante, maladie de crohn chez l'adulte, colite ulcéreuse, psoriasis chez l'adulte, l'adolescent et l'enfant, hidradénite suppurée, uvéite - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - adalimumabum - soluzione iniettabile in siringa preriempita - adalimumabum 40 mg, saccharum, polysorbatum 80, acidum aceticum glaciale, natrii hydroxidum corresp. natrium 0.26 mg, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - rheumatoide arthritis, polyartikuläre juvenile idiopathische arthritis, psoriasis-arthritis, ankylosierende spondylitis (morbus bechterew), morbus crohn bei erwachsenen sowie kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, hidradenitis suppurativa, uveitis - biotechnologika